Kevin D. Welch
Pacific Northwest National Laboratory
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Kevin D. Welch.
Antimicrobial Agents and Chemotherapy | 2007
Paul S. Hoffman; Gary Sisson; Matthew A. Croxen; Kevin D. Welch; W. Dean Harman; Nunilo Cremades; Michael G. Morash
ABSTRACT Nitazoxanide (NTZ) exhibits broad-spectrum activity against anaerobic bacteria and parasites and the ulcer-causing pathogen Helicobacter pylori. Here we show that NTZ is a noncompetitive inhibitor (Ki, 2 to 10 μM) of the pyruvate:ferredoxin/flavodoxin oxidoreductases (PFORs) of Trichomonas vaginalis, Entamoeba histolytica, Giardia intestinalis, Clostridium difficile, Clostridium perfringens, H. pylori, and Campylobacter jejuni and is weakly active against the pyruvate dehydrogenase of Escherichia coli. To further mechanistic studies, the PFOR operon of H. pylori was cloned and overexpressed in E. coli, and the multisubunit complex was purified by ion-exchange chromatography. Pyruvate-dependent PFOR activity with NTZ, as measured by a decrease in absorbance at 418 nm (spectral shift from 418 to 351 nm), unlike the reduction of viologen dyes, did not result in the accumulation of products (acetyl coenzyme A and CO2) and pyruvate was not consumed in the reaction. NTZ did not displace the thiamine pyrophosphate (TPP) cofactor of PFOR, and the 351-nm absorbing form of NTZ was inactive. Optical scans and 1H nuclear magnetic resonance analyses determined that the spectral shift (A418 to A351) of NTZ was due to protonation of the anion (NTZ−) of the 2-amino group of the thiazole ring which could be generated with the pure compound under acidic solutions (pKa = 6.18). We propose that NTZ− intercepts PFOR at an early step in the formation of the lactyl-TPP transition intermediate, resulting in the reversal of pyruvate binding prior to decarboxylation and in coordination with proton transfer to NTZ. Thus, NTZ might be the first example of an antimicrobial that targets the “activated cofactor” of an enzymatic reaction rather than its substrate or catalytic sites, a novel mechanism that may escape mutation-based drug resistance.
Journal of the American Chemical Society | 2013
Elliott B. Hulley; Kevin D. Welch; Aaron M. Appel; Daniel L. DuBois; R. Morris Bullock
Heterolytic cleavage of dihydrogen into a proton and a hydride ion is a fundamentally important step in many reactions, including the oxidation of hydrogen by hydrogenase enzymes and ionic hydrogenation of organic compounds. We report the facile, reversible heterolytic cleavage of H2 in a manganese complex bearing a pendant amine, leading to the formation of a manganese hydride and a protonated amine that undergo H(+)/H(-) exchange at an estimated rate of >10(7) s(-1) at 25 °C.
Journal of the American Chemical Society | 2008
Daniel P. Harrison; Kevin D. Welch; Adam C. Nichols-Nielander; Michal Sabat; William H. Myers; W. Dean Harman
Pyridine borane is combined with TpW(NO)(PMe(3))(eta(2)-benzene) to form a complex of the heterocycle, which upon treatment with acetone and acid yields the pyridinium complex [TpW(NO)(PMe(3))(eta(2)-pyH(+))]OTf. Deprotonation in the presence of acetic anhydride delivers the N-acetylpyridinium complex as a 10:1 mixture of coordination diastereomers. This acylpyridinium resists reaction with water or oxygen but readily reacts with acetone, pyrrole, indole, or acrolein and a weak base to stereoselectively form 1,2-dihydropyridine complexes. Treatment of the indole-derived analogue with CuBr(2) results in liberation of 3-(pyridin-2-yl)-1H-indole.
Archive | 2014
Elliott B. Hulley; Kevin D. Welch; Aaron M. Appel; Daniel L. DuBois; R. Morris Bullock
Related Article: Elliott B. Hulley , Kevin D. Welch , Aaron M. Appel , Daniel L. DuBois , and R. Morris Bullock|2013|J.Am.Chem.Soc.|135|11736|doi:10.1021/ja405755j
Organometallics | 2007
Weijun Liu; Kevin D. Welch; Carl Trindle; Michal Sabat; and William H. Myers; W. Dean Harman
Organometallics | 2010
Kevin D. Welch; William G. Dougherty; W. Scott Kassel; Daniel L. DuBois; R. Morris Bullock
Organometallics | 2007
Kevin D. Welch; Daniel P. Harrison; Edward C. Lis; Weijun Liu; and Rebecca J. Salomon; W. Dean Harman; William H. Myers
Organometallics | 2006
Kevin D. Welch; Philip L. Smith; Andrew P. Keller; William H. Myers; Michal Sabat; W. Dean Harman
Organometallics | 2005
William H. Myers; Kevin D. Welch; Peter M. Graham; Andrew P. Keller; Michal Sabat; Carl Trindle; W. Dean Harman
Organometallics | 2009
Daniel P. Harrison; Victor E. Zottig; George W. Kosturko; Kevin D. Welch; Michal Sabat; William H. Myers; W. Dean Harman